Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil and Hyperalgesia: Gradual Withdrawal Versus Immediate Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing a thyroid surgery~* male/female~* from the age of 18 until 65~* ASA physical status of I-III~* Knowledge of French, English or Dutch is required in order to be enrolled in this study.~Exclusion Criteria:~* Pregnancy~* hypo-/hyperthyroidism~* gastro-duodenal ulcer~* allergy or contraindications to one of the study drugs~* renal insufficiency~* liver insufficiency~* neuropsychiatric disturbance~* BMI \>30~* history of drug and alcohol abuse~* preoperative analgesic drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -\> 1.4 -\> 1 -\> 0.7-\> 0.5 -\> 0.35 -\> 0.25 -\> 0 ng/ml)
- NaCl 0.9% (Type: PLACEBO_COMPARATOR): Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -\> 1.4 -\> 1 -\> 0.7-\> 0.5 -\> 0.35 -\> 0.25 -\> 0 ng/ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).